Add time:08/16/2019         Source:sciencedirect.com

BackgroundEpidemiological studies indicate high serum 25(OH)D3 is associated with increased survival in breast cancer patients. Pre-clinical studies attributed this to anti-tumorigenic properties of its metabolite 1α,25(OH)2D3. However, 1α,25(OH)2D3 is highly calcemic and thus has a narrow therapeutic window. Here we propose another metabolite, 24R,25(OH)2D3, as an alternative non-calcemic vitamin D3 supplement.

We also recommend Trading Suppliers and Manufacturers of (24R)-20,24-Epoxy-5α-lanost-9(11)-ene-3β,6α,16β,25-tetrol (cas 11026-01-0). Pls Click Website Link as below: cas 11026-01-0 suppliers